Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aussie Pharma Pharmaxis Submits Bronchitol Application to China’s State FDA

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Sydney-based Pharmaxis submitted a clinical trial application to China's State FDA for chronic lung condition drug Bronchitol (mannitol) for treatment of bronchiectasis, the company announced March 7

You may also be interested in...



Sydney-Based Pharmaxis Gets FDA Green Light On Bronchitol SPA

PERTH, Australia - Sydney-based Pharmaxis and the U.S. FDA reached an agreement on a Phase III registration trial of Bronchitol (mannitol) for treatment of bronchiectasis through the special protocol assessment process, which will form the basis of the company's efficacy claim, PharmAxis announced June 20

Sydney-Based Pharmaxis Gets FDA Green Light On Bronchitol SPA

PERTH, Australia - Sydney-based Pharmaxis and the U.S. FDA reached an agreement on a Phase III registration trial of Bronchitol (mannitol) for treatment of bronchiectasis through the special protocol assessment process, which will form the basis of the company's efficacy claim, PharmAxis announced June 20

Australia, New Zealand Roundup: Pharmaxis, CSL, PHARMAC

Pharmaxis Completes Long-Term Safety Study Of Bronchitol

Related Content

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel